T HE COURSE of coronary artery disease frequently is altered by the development of acute thrombosis, a complication that plagues atherosclerotic vessels. Though progress has been made in treating this complication, current therapy is still far from satisfactory. Anticoagulants, effective though they may be in restricting further extension of the primary lesions or diminishing the incidence of new thrombi, have little influenee on the obstructing thrombus or its direct consequences. For these reasons considerable interest attaches to any procedure that might produce a rapid resolution of the obstructing thrombus. A medical approach, currently receiving considerable attention, involves the use of thrombolytic or clot-dissolving agents and is aimed at enzymatic lysis of fibrin, the major insoluble fibrous protein of the clot. On the basis of experimental observations such anl approach seenms entirely feasible, and the present report briefly reviews the progress made toward the achievement of this goal. It will be apparent that therapeutic methods useful in coronary artery thrombosis are still in the early stages of development but concepts and methods of real promise are emerging. These latter aspects are stressed in this communication, since they are basic to further therapeutic advances. Biochemical and Physiologic Considerations'-3
The disintegration of blood clot structure or clot lysis, which occurs when human blood clots are stored under sterile conditions, has long been terined fibrinolysis. Similarly, following suddeni death, postmortem blood clots. Circulation, Volume XXII, October 1960 formed through the vascular tree, dissolve over a period of several hours. Medical thought has been uniquely stimulated by such observations, for these spontaneous events of nature have implied that through proper use of physiologic enzyme systems, it might be possible to induce thrombolysis* in living subjects for therapeutic purposes.
Thrombi, as well as the serum, of all mammals contain a significant concentration of an enzyme precursor, plasminogen, which when acted upon by various specific activators, is converted to a proteolytic enzyme, plasmin.t Plasmin has a spectrum of enzymatic activity similar to but not identical with that of trypsin. Plasmin digests proteins of such physiologic importance as fibrin, fibrinogen, accelerator globulin, and some components of complement; alternative substrates, useful for assay purposes, include casein and certain synthetic amino acid esters.
Activation of plasminogen may occur spontaneously (under restricted laboratory conditions), but otherwise results from activation by specific kinases or activators. Such specific plasminogen activators can be extracted from all organ tissues, except the placenta and liver, and are found in plasma, urine (the urinary activator is named urokinase), and other body secretions. The ubiquitous presence of plasminogen activators in virtuallv all tissues and body fluids reflects the role of these substances in homeostasis.
The plasminogen-plasmin system seems admirably suited for effecting clot dissolution, not on the basis of any specificity of plasmin *The term thrombolysis will be used to describe the reaction by which thrombi (or clots) are lysed. The adjective thrombolytic will be used to designate biochemical moieties capable of inducing thrombolysis. tPlasminogen and plasmiin were for a brief period referred to as profibrinolysin and fibrinolysin. Happily this latter terminology, conveying an unjustified connotation of specificity, is now virtually obsolete. 619 for fibrin, but rather by virtue of the distribution of plasminogen and inihibitors. This distribution, dependent upon the separate location of plasminogeni in either thrombi or plasma, profoundly influences the consequences of plasminogen activation.
Plasmin formed by activation of plasminogen within a thrombus has only fibrinl available as its major substrate and is relatively uninhibited in its action. Thus activation of plasminogen to plasmin within the interstices of a thrombus results in extensive clot dissolution without any other manifestations of proteolysis. In contrast, plasmin formed in, or added to, plasma is usually rapidly inhibited by the large amounts of naturally occurring eirculating antiplasmin. When unusually large amounts of plasmin are formed in plasma, then a number of plasma proteins may be acted upon without discriminatioii.
The Induction of a Thrombolytic State in Man Physiologic Considerations
Theoretically there exist two approaches toward the therapeutic use of the plasminogen-plasmin system. Either the activated enzyme, plasmin,* could be infused into patients or alternatively, plasminogen activators could be similarly used.t In both instances, on theo-*This refers to the biochemical entity, plasmin, and not to the preparations under clinical trial or experimental study which also have been referred to as "'plasmin. " The latter are mixtures of activator (usually streptokinase) and human plasmin; the major portion of their fibrinolytic activity can be attributed to their content of activator. fAnother possible approach is to control the release of endogenous activator by pharmacologic agents. Though this may ultimately prove to be a useful method, the release of activator by pharmacologic meanis (nicotinic acid, bacterial pyrogenis, etc.) so far has been inconsistent, variable in duratioin, and associated with the rapid development of tolerance.
Proteolytic einzymiies (other thain plasmin) currenltly available in purified form and capable of digesting fibrin also have been considered for thrombolytic therapy. Their use, in vivo, in amounts sufficient to produce clot dissolution probably will be extremely hazardous, if not catastrophic, for they have extensive effects on a great variety of plasma proteins. retical grounds, increased activity of the plasminogen-plasmin system might be inferred to result; consequently either approach might, in theory, be a valid one. However, experiment reveals that the practical limitations inherent in the use of the enzyme plasmin are so great that the only feasible and indeed only physiologic way to incite increased plasma thrombolytic activity is to use plasminogen activators. The basis for this conclusion is examined below: The Plasmin Approach4 5 The top section of table 1 displays the simple theoretical concept that has been held to justify the use of plasmin infusion in patients. Though plasmin will digest fibrin under in vitro conditions, there are grave difficulties attendant on the use of this enzyme in vivo (bottom section of table 1). First, plasma exerts powerful inhibitory effects against plasmin; when extremely small doses of plasmin are injected (as in the clinical trials so far conducted with "plasmin preparations"), negligible enzymatic effects are produced in vivo. Second, and of much greater fundamental importance, is evidence that the infusion of sufficient doses of the enzyme plasmin to produce detectable enzymatic effects in vivo will cause a state of excessive plasma proteolysis or "fibrinolysis" as a disease state. Such conditions when recognized clinically (usually following operative procedures or obstetric complications) are associated with a hem orrhagie diathesis of severe and sometimes fatal intensity. The features characterizing this diathesis are shown in table 2, where it is indicated that they stem primarily from the biochemical lesion of fibrinogen proteolysis.6 It is evident from in vitro experiment, from animal experiment, and from study of "fibrinolytic" pheniomena occurring in human disease states2 that the attempted therapeutic use of the enzyme plasmin is unlikely to prove effective in man. Similar considerations apply to the use of all other proteolytic enizymiies so far tested. In all instances low doses of these substances are rendered biochemically inactive by plasma inhibitors; high doses, sufficient to overwhelm plasma in-Circulation, Volume XXII, October 1960 hibitory mechanisms, would induce a state of general plasma proteolysis and an associated severe coagulation defect.
The Plasminogen Activator Approach As indicated in table 3 (top section), plasminogen activators produce a thrombolytic action whether they are present in purified systems or in plasma. Substantial amounts of plasminogen are contained within the interstices of thrombi or fibrinous deposits and diffusion or absorption of a plasminogen activator to the thrombus causes activation of the intrinsic clot plasmin-ogen and thrombolysis.7 Though quantitative differences are apparent among the actions of the different activators listed in table 3, their qualitative modes of action are similar. The presence of plasminogen activator in plasma causes activation of plasma plasminogen as well as clot plasmino-Circulation, Volume XXII, October 1960 gen, but clinical experience8 has shown that plasma inhibitory mechanisms against plasmin are so effective that the resulting coagulation defect is usually of a minor nature.
The Induction of a Thrombolytic State in Man with Plasminogen ActivatQrs
To date streptokinase has been the only plasminogen activator prepared in sufficient quantity and purity for clinical trial. Its intravenous infusion has been shown to produce, both in man and animals, intensely heightened plasma thrombolytic activity, i.e., levels several hundred times the resting level.8 There is indisputable evidence that the proper systemic use of this agent will produce lysis of experimentally induced thrombi in the experimental animal9"10 and in man ;11 evidence of a less certain but highly suggestive nature indicates that streptokinase therapy The top portion of the table displays the mechanism by which plasminogen activators cause thrombolysis in purified systems or in plasma. However, in immune plasma, containing specific streptokinase antibody, the action of streptokinase may be inhibited (bottom portion of the table).
will lyse thrombi produced secondary to human disease states. 12 Unfortunately, as is indicated in the lower portion of table 3, immunologic considerations arise when streptokinase is used for therapeutic purposes. Since streptokinase is antigenic to man and streptococcal infection is a relatively common event, human plasma eontains a variable concentration of specific streptokinase antibody. Union of streptokinase and free antibody renders streptokinase biochemically inert and consequently, where therapeutic action is required, the initial streptokinase dosage, determined after titration of the patient's antibody, may vary over a wide range. The extent and importance of this fact has not always been realized by investigators who, as a consequence, have frequently used biochemically impotent preparations. When streptokinase is to be used as a therapeutic agent, it is mandatory to assay the patient 's plasma for streptokinase antibody. In no other way can a dose be calculated that will produce a consistent biochemical response in man.
The literature, even that of recent date, abounds with claims that plasmin (sometimes called fibrinolysin) is an effective thrombo-lytic agent in vivo.13 These claiims are unsubstantiated and have arisen because of the use by several investigators of inadequately assayed and characterized "plasmin preparations. " Adequate analytic mnethods reveal these preparations to be grossly contaminated with plasminogen activator (streptokinase) and the major portion of their in vitro biochemical activity can be attributed to the presence of streptokinase rather than plasmin. Consequently when such preparations are infused into iean, their biochemical activity may be neutralized in the presence of specific ailtibody. Neglect of this fact has led to the marketing of a preparation described as huinan fibrinolysin (Actase) which, on infusion into man, exerts negligible biochemical effects. '4 Solution of the problem of clot dissolution in man by enzymatic! means requires, as its immediate objective, the institution and maintenance in vivo of a controlled biochemical state in which the circulating plasma of the patient is endowed with the ability to lyse preformed thrombi, yet without significant hazard or toxic effect. In this respect an analogy may be drawn to anticoagulant therapy in which the controlled state is one of hypocoagulability and the ultimate objective is inhibition of clot formation. The purpose of this analogy is to stress the requirement for assay methods that measure the extent to which the thrombolytic activity of the patient's circulating plasma has been enhanced. Obviously such laboratory methods, in order to yield relevant data, should employ the patient 's plasma and conditions that closely mimic the in vivo problem. Unfortunately much of the current work on fibrinolytic therapy is open to serious criticism, since observations of this type have either not been made or have been inadequately tested. In developing our own studies, we have relied heavily on a thrombolytic assay that measures the ability of the patient's plasma to dissolve preformed human plasma clots.7
Special Considerations in the Treatment of Coronary Heart Disease The treatment of coronary artery disease and its complications by thrombolytic therapy present several difficult problems. First, it is evident that only the secondary complication of thrombosis rather than the primary arterial disease can be successfully treated in this manner. Second, it is known that coronary artery occlusion may be due to causes other than thrombosis and that diagnostic methods for making the distinction are lacking; arterial lesions such as those caused by subintimal hemorrhage could conceivably be worsened by the suggested therapy. Third, it is not yet firmly established that the restoration of blood supply to an acutely infareted area of myocardium is always desirable. Finally, the therapeutic preparations used for the treatment of these often critically ill patients must be shown to be free of deleterious effect.
On the other hand, substantial benefits could follow the early enzymatic lysis of a coronary thrombus and the consequent restoration of blood flow to the acutely infareted or acutely ischemic myocardium. These might include reduction of the final area of muscle infaretion, reduction of the degree of electrical instability during the early critical stage of infarction, the prevention or removal of mural thrombi, and the prevention of extracardiae thromboembolic complications.
Circulation, Volume XXII, October 1960 Animal Studies Two groups of workers have studied the effect of lysing a thrombus obstructing a coronary artery by enzymatic means. Though in neither instance did the animal model approximate to the situation commonly found in the human, the results are of considerable interest.
Agress et al.15 passed a catheter through the left carotid artery of dogs (closed chest preparations) and injected into the coronary arteries small fibrin partieles, prepared from human plasma and sieved. Embolization with fibrin particles was continued until persistent and in some cases progressive electrocardiographic evidence of myocardial damage was observed. Half the dogs were treated with 1 to 6 intravenous infusions of trypsin over an 8-day period and the other half were maintained as controls. Comparison of treated and control animals suggested, by all the criteria used (degree of final infaretion, presence of visible clots, degree of vessel patency, improvement in electrocardiographic findings), that the trypsin therapy had benefited the treated dogs.
Ruegsegger et al.'6 produced myocardial infaretion in dogs by an open-chest procedure during which a serum-induced thrombus was formed in the anterior descending coronary artery. Systemic "plasmin" therapy, with a mixture of streptokinase and human plasmin, was administered within a few hours; after a variable time interval arteriographic evidence of partial or complete thrombus dissolution was obtained. The authors suggested that, as a result of the "plasmin" therapy, the final area of muscle infaretion had been somewhat reduced in size and that judged on histologic grounds the degree of injury reaction was lessened.
The experimental results of these two groups, though failing to afford conclusive evidence of the benefits of enzyme therapy in experimental myocardial infaretion, are of significance. Though details are lacking, it may be inferred from the data that hemostatic defects of a severe degree resulted from the state of general plasma proteolytic activity in-duced by the enzyme therapy, yet in neither instance was excessive hemorrhagic reaction noted in the infaret. The implications of this finding may be relevant to the problem of enzyme treatment in the hunman.
Thrombolytic Therapy in Human Coronary Heart
Disease
The clinical investigation of thrombolytic therapy in coronary heart disease, because of the many serious problems involved, has only recently commenced. Though the literature contains reports on the enzymatic treatment of only one small series of patients suffering from acute myocardial infaretion, important information has already been obtained.
The purpose of the study12' 17 was to evaluate the effect of a 30-hour period of inteiisive thrombolytic therapy in patients suffering from early myocardial infaretion. Since there is theoretic reason to advocate the early use of enzyme therapy and some grounds for believing that its later use would be at least relatively ineffective, the patients were divided into a main early treatment group and a subsidiary late treatment group. The early treatment group comprised 19 patients whose infaret (judged on the basis of symptomatology) had occurred 5 to 16 hours previously (average 9 hours). The late treatment group comprised 3 seriously ill patients in whom infaretion had taken place 34 to 65 hours previously and in whom enzyme treatment was only undertaken as a course of last resort; all died during or following treatmrent.
The early treatment group received intensive streptokinase therapy for 30 hours and were later maintained on anticoagulant treatment for at least the duration of their hospital stay. Serial biochemical measurements during the treatment period indicated that intensive plasma thrombolytic activity (100 to 500 [kg.
of fibrin lysed per hour per ml. of plasma) was developed and maintained for 30 hours. No patient died during the early acute phase, but 1 patient died from reinfaretion 3 weeks later while receivinig anticoagulant treatment.
The mortality of the treated group was less than that of control patients selected by a double-blind procedure (4 of 11 died) and less than that of the hospital mortality during the same period (19.5 per cent). Nevertheless, because of the small numbers involved, statistical testing gave a p value of 0.2. Restudy of the group 4 to 6 months later revealed no evidence of aneurysm formation, and only ninimal evidenee of cardiac enlargement.
Electrocardiographic findings were relatively favorable and neither the patients' symuptoms nor physical examination disclosed unusual features.'2 Autopsy evidenice revealed no findinig suggesting that the treatment had exerted a deleterious effect on the myocardium.
Discussion
Hitherto the medical armamentarium has lacked measures to lyse thrombi or emboli within the vaseular tree. Current ilivestigation has progressed to the point where such measures may soon become available to the practicing physician. Since there are still a number of problems that must be solved before safe and effective agents can be made generally available, it has been the purpose of this communication to stress both present difficulties as well as encouraging results. The premature release of either impotent or potentially toxic agents will serve only to delay the ultimate achievement of practical thrombolytic therapy.
On the debit side, it is evident that enzymnatic therapy is not sufficiently developed to permit its trial under any except clinical investigative circumstances. Clinical experience has been limited and methods are insufficiently standardized to permit aim extended trial. Unusual difficulty has been experienced in preparing sufficient quantities of highly purified streptokinase (the only plasiuinogen activator so far tested) for large-scale clinical use. Current intense developmental work on this problem could prove successful in the near future, but at present each separate lot of streptokinase inust be cautiously tested in man (to establish its freedoin froin pyrogenie impurity) before its serious therapeutic use can be contemplated. Streptokinase, because of its antigenic miature, is not an ideal plasmniiogen activator for cliniical use; this prop-Circulation, Volume XXII, October 1960 erty imposes certain restrictions upon and complicates its use, for individual patient dosage must be established after prior assay for plasma antibody.
On the credit side it can be claimed that recent contributions to physiologic knowledge have not only elucidated the mechanism by which clot lysis proceeds in vivo, but have emphasized the considerable possibilities inherent in the therapeutic employment of this mechanism. The control in patients of thrombolytic mechanisms has proved to be possible, though at present the laboratory tests required for this purpose are still of an undesirably complex nature. The limited clinical evidence not only supports the feasibility of this therapeutic approach but, perhaps more important for coronary heart disease, it indicates that enzymatic treatment is not associated with deleterious secondary effects on infarcted myocardial tissue. Consequently, in principle at least, large-scale trial of enzymatic therapy in coronary heart disease may be indicated, though this should await the solution of certain technical problems. Undoubtedly the greatest need for the future is for the development of a nonantigenic plasminogen activator; current work with urokinase (the naturally occurring urinary plasminogen activator) offers promise in this connection.
It is the authors' conviction18 that the establishment of sound scientific principle should take precedence over practical trial based on poorly controlled or empirical observations. Recent progress with the former aspect has been gratifying and therapeutic principles now seem to be firmly established; it may be anticipated that their practical application will follow shortly.
Summario in Interlingua Usque nunc le armamentario medical ha includite nulle mesuras pro effectuar le lyse de thrombos o embolos intra le arbore vascular. Le investigationes currentemenite in progresso ha attingite un puncto ubi nos pote predicer que tal mesuras va tosto esser disponibile al medico practic. Proque il remane un numero de problemas que debe esser resolvite ante que salve e efficace agentes pote esser lanceate al uso general, le objectivo del presente communication esseva signalar tanto le difficultates ancore existente Circulation, Volume XXII, October 1960 eomo etiam le incoragiante resultatos jam obtenite.
Al latere negative, il es evidente que le therapia enizymatic es non ancora sufficientemente disveloppate pro justificar su application excepte intra le quadro de un investigation clinic.
Al latere positive, on pote insister que recente contributiones a nostre cognoscentias physiologic ha non solmente elucidate le mechanismo que representa le lyse del coagulo in vivo sed ha etiam fortificate nostre fide in le possibilitate de traducer ille mechanismo in un forma de exploitabilitate therapeutic. Le regulation del mechanismo thrombolytic intra le patiente se ha provate effectuabile, ben que al tempore presente le tests de laboratorio que es requirite pro ille objectivo es ancora de natura regrettabilemente complexe.
II es le conviction del autor que le establimento de solide principios scientific debe preceder le essayos practic a base de observationes mal regulate o purmente empiric. Recente progressos con respecto al principios es promittente. Le theoria therapeutic pare esser firmemente establite, e le expectation es justificate que su exploitation practic va tosto sequer.
